Roche strongly outperforms market in first quarter

RocheThe Roche Group recorded total sales of 11.6 billion Swiss francs in the first quarter of 2009, an increase of 8% in local currencies (7% in Swiss francs; -1% in US dollars)1 compared with the year-earlier period. Growth was driven mainly by continued strong sales of key products in the Group's oncology, virology, ophthalmology and inflammation portfolios, and of Roche Diagnostics' immunoassay systems.

  • Group sales up 8% in local currencies and 7% in Swiss francs to 11.6 billion Swiss francs (-1% in US dollars)
  • Roche completes transaction to take full ownership of Genentech — key decisions on organisational structure and management appointments taken
  • Full-year outlook to be updated to include impact of Genentech transaction and communicated with half-year results

Pharmaceuticals Division

  • Sales advance 8% in local currencies and Swiss francs - around twice as fast as the global market - driven by key products in the oncology, virology, ophthalmology and inflammation portfolios
  • Encouraging response to rollout of RoActemra for rheumatoid arthritis in first EU countries
  • MabThera receives EU approval as first-line treatment for chronic lymphocytic leukemia
  • FDA advisory panel unanimously supports use of Avastin in patients with previously treated glioblastoma brain cancer
  • Results of phase III trial of Herceptin in HER2-positive inoperable stomach cancer (ToGA) released a year earlier than expected due to significant overall survival benefit

Diagnostics Division

  • Divisional sales grow 8% in local currencies and 3% in Swiss francs, well ahead of the global market
  • Professional Diagnostics and Tissue Diagnostics are key growth drivers
  • Acquisition of innovatis strengthens Roche Applied Science's cell analysis portfolio

Unless otherwise stated, all growth rates are in local currencies

Commenting on the first three months of 2009, Roche CEO Severin Schwan said: "With growth of 8%, the Roche Group's sales developed very well in the first three months of 2009. Sales in both divisions continued to grow significantly faster than their respective markets. We are therefore confident that we can achieve our full-year targets. Following the friendly merger agreement with Genentech and rapid completion of the transaction, we have made considerable progress with integration activities. We are delighted that Art Levinson will continue to support us in an active role and that many outstanding individuals from both Genentech and Roche have committed themselves to driving forward the combined businesses. We will update our full-year outlook to include the impact of the Genentech transaction when we announce our half-year results."

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Most Popular Now

Lilly begins world's first study of a potential CO…

Eli Lilly and Company (NYSE: LLY) announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This inve...

GSK COVID-19 vaccine development collaboration wit…

GSK's scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover announced the initiati...

Novartis research shows technology talent increasi…

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing res...

Pfizer and BioNTech announce early positive data f…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT16...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Novartis resolves legacy litigation matters, final…

Novartis has finalized its previously disclosed agreement with the US Attorney's Office for the Southern District of New York, the New York State Attorney General, and re...

Sanofi and Translate Bio expand collaboration to d…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to ...

Bayer supports "The Challenge Initiative…

Today Bayer announced the support of "The Challenge Initiative" ("TCI" hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public...

Newer variant of COVID-19-causing virus dominates …

Research out today in the journal Cell shows that a specific change in the SARS-CoV-2 coronavirus virus genome, previously associated with increased viral transmission an...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...